CoChat
Sign Up
Cited by 92

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoter

Hannigan, Adèle, Smith, Paul, Kalna, Gabriela, Lo Nigro, Cristiana, Orange, Clare, O’Brien, Darren I., Shah, Reshma, Syed, Nelofer, Spender, Lindsay C., Herrera, Blanca, Thurlow, Johanna K., Lattanzio, Laura, Monteverde, Martino, Maurer, Meghan E., Buffa, Francesca M., Mann, Jelena, Chu, David C.K., West, Catharine M.L., Patridge, Max, Oien, Karin A., Cooper, Jonathan A., Frame, Margaret C., Harris, Adrian L., Hiller, Louise, Nicholson, Linda J., Gasco, Milena, Crook, Tim, Inman, Gareth J.·2010·Journal of Clinical Investigation
DOI 10.1172/jci36125
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci36125

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dab2 loss in head and neck cancer compromises the tumor suppressor function of TGF-beta while enabling its tumor-promoting activities, and Dab2 is a molecular switch for TGF-beta from a tumor suppressor to a promoter.

    “another study found that Dab2 dose not impact the canonical TGF-beta pathway but Dab2 loss in head and neck cancer compromised the tumor suppressor function of TGF-beta, while enabling its tumor-promoting activities, and concluded that Dab2 is a molecular switch for TGF-beta from a tumor suppressor to a promoter (Hannigan et al., 2010).”

    From Endocytosis and Physiology: Insights from Disabled-2 Deficient Mice (2016) · cites this paper as Hannigan et al., 2010

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 55

  1. 10.1038/nrc1208 · DOI
  2. Pardali, 2007, Biochim Biophys Acta., 1775, 21
  3. 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
  4. Massague, 2008, Cell., 134, 215, 10.1016/j.cell.2008.07.001 · DOI · Paper page
  5. 10.1016/j.cytogfr.2005.09.006 · DOI
  6. 10.1016/S0959-437X(01)00259-3 · DOI
  7. 10.1073/pnas.1633291100 · DOI
  8. Shi, 2003, Cell., 113, 685, 10.1016/S0092-8674(03)00432-X · DOI
  9. 10.1038/nature02006 · DOI
  10. 10.1101/gad.1350705 · DOI
  11. 10.1016/j.cytogfr.2005.09.001 · DOI
  12. Tsukazaki, 1998, Cell., 95, 779, 10.1016/S0092-8674(00)81701-8 · DOI
  13. Lin, 2004, Nature., 431, 205, 10.1038/nature02783 · DOI
  14. 10.1093/emboj/20.11.2789 · DOI · Paper page
  15. 10.1093/emboj/21.7.1555 · DOI · Paper page
  16. 10.1083/jcb.200812160 · DOI · Paper page
  17. 10.1038/sj.onc.1201678 · DOI
  18. 10.1074/jbc.M210628200 · DOI
  19. 10.1093/emboj/cdg286 · DOI · Paper page
  20. 10.1038/sj.onc.1201769 · DOI · Paper page
  21. 10.1038/sj.onc.1202649 · DOI · Paper page
  22. 10.1210/en.139.8.3542 · DOI
  23. Bagadi, 2007, Breast Cancer Res Treat., 104, 277, 10.1007/s10549-006-9422-6 · DOI · Paper page
  24. Anupam, 2006, World J Gastroenterol., 12, 6041, 10.3748/wjg.v12.i37.6041 · DOI · Paper page
  25. Yang, 2006, Am J Pathol., 169, 258, 10.2353/ajpath.2006.060036 · DOI
  26. 10.1158/1078-0432.CCR-07-0287 · DOI
  27. 10.1172/JCI31457 · DOI
  28. 10.1016/j.cell.2007.02.005 · DOI · Paper page
  29. Simon, 2009, Nat Rev Mol Cell Biol., 10, 697, 10.1038/nrn2731 · DOI
  30. 10.1007/s00439-002-0804-5 · DOI
  31. 10.1158/0008-5472.CAN-06-3322 · DOI · Paper page
  32. 10.1074/jbc.M501150200 · DOI · Paper page
  33. 10.1074/jbc.M500974200 · DOI · Paper page
  34. 10.1074/jbc.273.33.21145 · DOI
  35. 10.1074/jbc.275.15.11320 · DOI
  36. 10.1128/MCB.25.24.10731-10744.2005 · DOI
  37. 10.1124/mol.62.1.65 · DOI
  38. 10.1073/pnas.77.6.3494 · DOI
  39. Moses, 1981, Cancer Res., 41, 2842
  40. 10.1038/cr.2008.316 · DOI
  41. Guasch, 2007, Cancer Cell., 12, 313, 10.1016/j.ccr.2007.08.020 · DOI
  42. 10.1016/j.ccr.2007.10.002 · DOI
  43. Bruna, 2007, Cancer Cell., 11, 147, 10.1016/j.ccr.2006.11.023 · DOI
  44. 10.1093/nar/gni130 · DOI
  45. Oft, 2002, Nat Cell Biol., 4, 487, 10.1038/ncb807 · DOI
  46. Kang, 2003, Cancer Cell., 3, 537, 10.1016/S1535-6108(03)00132-6 · DOI
  47. 10.1111/j.1349-7006.2007.00606.x · DOI
  48. 10.1016/j.gde.2005.12.009 · DOI
  49. Saunier, 2006, Curr Cancer Drug Targets., 6, 565, 10.2174/156800906778742460 · DOI
  50. Thurlow, 2010, J Clin Oncol., 28, 2881, 10.1200/JCO.2009.24.8724 · DOI
  51. 10.1016/S0006-291X(02)02751-1 · DOI
  52. 10.1080/00207160701210158 · DOI
  53. 10.1158/0008-5472.CAN-06-0186 · DOI
  54. 10.1016/S1097-2765(02)00585-3 · DOI
  55. 10.1016/0277-5379(87)90117-9 · DOI

Cited by

Sorted by citations

Metadata

Authors
Hannigan, A., Smith, P., Kalna, G., Lo Nigro, C., Orange, C., O’Brien, D. I., Shah, R., Syed, N., Spender, L. C., Herrera, B., Thurlow, J. K., Lattanzio, L., Monteverde, M., Maurer, M. E., Buffa, F. M., Mann, J., Chu, D. C. K., West, C. M. L., Patridge, M., Oien, K. A., Cooper, J. A., Frame, M. C., Harris, A. L., Hiller, L., Nicholson, L. J., Gasco, M., Crook, T., & Inman, G. J.
Venue
Journal of Clinical Investigation
Publisher
American Society for Clinical Investigation
Published
2010-08-02
Volume
120
Issue
8
Pages
2842-2857
ISSN
0021-9738
DOI
10.1172/jci36125
Cited by
92
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review